paediatrics Brussels 17

AREN0532/AREN0533: 4-year EFS

NWTS-5

AREN0532/ AREN0533

Stage I/II LOH 74.9%

83.9%

Stage III/IV LOH 65.9%

91.5%

Grade 3 or higher hematological toxicity seen with Regimen M in 60% of patients

Conclusion: Regimen M therapy improved EFS for Stage III/IV FH with LOH 1p and 16q compared to historical comparison group treated with DD4A. The benefit of DD4A for Stage I/II FH LOH 1p and 16q is less clear.

Dix DB et al. J Clin Oncol 33, 2015 (suppl; abstr 10009)